Wei‐Pang Chung

2.0k total citations
40 papers, 375 citations indexed

About

Wei‐Pang Chung is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Wei‐Pang Chung has authored 40 papers receiving a total of 375 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Wei‐Pang Chung's work include Cancer Treatment and Pharmacology (9 papers), HER2/EGFR in Cancer Research (8 papers) and Advanced Breast Cancer Therapies (8 papers). Wei‐Pang Chung is often cited by papers focused on Cancer Treatment and Pharmacology (9 papers), HER2/EGFR in Cancer Research (8 papers) and Advanced Breast Cancer Therapies (8 papers). Wei‐Pang Chung collaborates with scholars based in Taiwan, United States and South Korea. Wei‐Pang Chung's co-authors include Youngil Youm, Seock‐Ah Im, Wu‐Chou Su, Hui‐Ping Hsu, Ya‐Ting Hsu, Winnie Yeo, Zbigniew Nowecki, Ping‐Yen Liu, Vatsala Karwe and Hannah Dry and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Wei‐Pang Chung

37 papers receiving 366 citations

Peers

Countries citing papers authored by Wei‐Pang Chung

Since Specialization

Citations

This map shows the geographic impact of Wei‐Pang Chung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wei‐Pang Chung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wei‐Pang Chung more than expected).

Fields of papers citing papers by Wei‐Pang Chung

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wei‐Pang Chung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wei‐Pang Chung. The network helps show where Wei‐Pang Chung may publish in the future.

Co-authorship network of co-authors of Wei‐Pang Chung

This figure shows the co-authorship network connecting the top 25 collaborators of Wei‐Pang Chung. A scholar is included among the top collaborators of Wei‐Pang Chung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wei‐Pang Chung. Wei‐Pang Chung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Circulating CD3 ⁺ CD8 ⁺ T Lymphocytes as Indicators of Disease Status in Patients With Early Breast Cancer 2025 ·PubMed ·(unknown), Yi‐Ling Chen, Wei‐Pang Chung, (unknown), (unknown), Hui‐Ping Hsu	0
2	CD36 inhibition enhances the anti-proliferative effects of PI3K inhibitors in PTEN-loss anti-HER2 resistant breast cancer cells 2025 ·Cancer & Metabolism ·(unknown), Wei-Lun Huang, (unknown), (unknown), Ting‐Yu Kao, Wei‐Pang Chung, Kung-Chia Young	2
3	Primary Cardioprotective Effect of Sacubitril/Valsartan in Breast Cancer Patients Receiving Adjuvant Therapy 2025 ·European Journal of Heart Failure ·(unknown), (unknown), Wei‐Pang Chung, (unknown), (unknown), (unknown), Hui‐Ping Hsu, (unknown), (unknown), Pei‐Fang Su, Chao‐Ming Hung, Wei‐Chuan Tsai, Yen‐Wen Liu, Ping‐Yen Liu	2
4	A novel long non-coding RNA MIR4500HG003 promotes tumor metastasis through miR-483-3p-MMP9 axis in triple-negative breast cancer 2024 ·Cell Death and Disease ·(unknown), (unknown), (unknown), Forn-Chia Lin, Yu‐Chia Chen, (unknown), Po‐Shun Wang, (unknown), (unknown), Cheng‐Han Lin, Yao‐Lung Kuo, Wei‐Pang Chung, Hui-Chuan Cheng, Michael Hsiao, Chia-Ning Yang, Pei‐Jung Lu	5
5	Benign polymorphisms in the BRCA genes with linkage disequilibrium is associated with cancer characteristics 2024 ·Cancer Science ·(unknown), (unknown), (unknown), Wei‐Pang Chung, Chih‐Yang Wang, Pai‐Sheng Chen, Chun Hei Antonio Cheung, Chih‐Peng Chang, Hui‐Ping Hsu	3
6	Sacituzumab govitecan in HR+HER2− metastatic breast cancer: the randomized phase 3 EVER-132-002 trial 2024 ·Nature Medicine ·Binghe Xu, Shusen Wang, Min Yan, Joohyuk Sohn, Wei Li, (unknown), Xiaojia Wang, Ying Wang, Seock‐Ah Im, Dongdong Jiang, T. Valdez, (unknown), Yiran Zhang, Yi‐Lin Yan, Kimberly M. Komatsubara, Wei‐Pang Chung, Fei Ma, Ming‐Shen Dai	14
7	Real-life analysis of neoadjuvant-therapy-associated benefits for pathological complete response and survival in early breast cancer patients - role of trastuzumab in HER2+ BC and platinum in TNBC 2023 ·Frontiers in Oncology ·Wei‐Pang Chung, (unknown), (unknown), (unknown), Hsin‐Wei Su, Shang‐Yun Liu, Huang‐Tz Ou	0
8	377O A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03 2023 ·Annals of Oncology ·(unknown), Shanu Modi, Wěi Li, Y.H. Park, Wei‐Pang Chung, S-B. Kim, Javier Cortés, Toshinari Yamashita, José Luiz Pedrini, S-A. Im, L-M Tseng, Nadia Harbeck, (unknown), G. Curigliano, E. Mathias, Jillian Cathcart, (unknown), Shahid Ashfaque, Anton Egorov, Fabrice André	24
9	Risk of retinal vein occlusion in colorectal cancer patients receiving anti-vascular endothelial growth factors – a population-based cohort study 2023 ·BMC Cancer ·(unknown), Wei‐Pang Chung, Shih‐Chieh Shao, Edward Chia‐Cheng Lai, Yi‐Chen Chen, Chung‐Han Ho	0
10	FTY720 in resistant human epidermal growth factor receptor 2-positive breast cancer 2022 ·Scientific Reports ·Wei‐Pang Chung, Wei-Lun Huang, (unknown), (unknown), (unknown), Chun Hei Antonio Cheung, Wu‐Chou Su	8
11	PS2-1 Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03 2022 ·Annals of Oncology ·Seock‐Ah Im, Binghe Xu, Sung‐Bae Kim, Wei‐Pang Chung, Winnie Yeo, Min Hwan Kim, Ling‐Ming Tseng, (unknown), Chiun‐Sheng Huang, Jee Hyun Kim, Joanne Wing Yan Chiu, Toshinari Yamashita, Wěi Li, Caleb Lee, (unknown), (unknown), Yuji Nishiyama, (unknown), Javier Cortés, Hiroji Iwata	3
12	Comparative Treatment Persistence with Bone-Targeting Agents Among Asian Patients with Bone Metastases from Solid Tumors: A Multinational Retrospective Cohort Study 2022 ·BioDrugs ·(unknown), Philip Chun-Ming Au, Yeon‐Hee Baek, Ching‐Lung Cheung, Wei‐Pang Chung, Ju Hwan Kim, Nora J. Kleinman, Tai‐Chung Lam, (unknown), Tzu‐Chieh Lin, Ju‐Young Shin, Chor‐Wing Sing, Ian Chi Kei Wong, Edward Chia‐Cheng Lai	4
13	Bone-targeting agents in major solid tumour metastases: a multinational cohort study 2022 ·BMJ Supportive & Palliative Care ·Ju Hwan Kim, (unknown), Philip Chun-Ming Au, Yeon‐Hee Baek, Ching‐Lung Cheung, Wei‐Pang Chung, Nora J. Kleinman, Tai‐Chung Lam, (unknown), Tzu‐Chieh Lin, Ju‐Young Shin, Chor‐Wing Sing, Ian Chi Kei Wong, Edward Chia‐Cheng Lai	1
14	The prognosis of early-stage breast cancer in extremely young female patients 2021 ·Medicine ·Wei‐Pang Chung, (unknown), Yaping Chen, Ya‐Ting Hsu, (unknown), (unknown), Hui‐Ping Hsu	5
15	Treatment-associated survival outcomes in real-world patients with de novo metastatic triple-negative breast cancer: Age as a significant treatment effect-modifier 2021 ·Journal of the Formosan Medical Association ·Wei‐Pang Chung, (unknown), (unknown), (unknown), (unknown), Huang‐Tz Ou	5
16	Development of the CK‐MB‐1 trastuzumab‐resistant HER2‐positive breast cancer cell line and xenograft animal models 2021 ·Cancer Medicine ·Wei‐Pang Chung, Wei‐Lun Huang, (unknown), (unknown), (unknown), Wu‐Chou Su	1
17	False-negative frozen section of sentinel nodes in early breast cancer (cT1-2N0) patients 2021 ·World Journal of Surgical Oncology ·(unknown), (unknown), Yaping Chen, Yao-Lung Kuo, Wei‐Pang Chung, Ya‐Ting Hsu, (unknown), Hui‐Ping Hsu	3
18	Real-time exercise reduces impaired cardiac function in breast cancer patients undergoing chemotherapy: A randomized controlled trial 2021 ·Annals of Physical and Rehabilitation Medicine ·Wei‐Pang Chung, (unknown), Ya‐Ting Hsu, Ching‐Hsia Hung, Ping‐Yen Liu, Yen-Wen Liu, Shih‐Hung Chan, Kun‐Ling Tsai	36
19	Invasive lobular carcinoma of breast with synchronous colon metastasis 2017 ·Formosan Journal of Surgery ·(unknown), (unknown), Wei‐Pang Chung, (unknown), (unknown), (unknown), (unknown), (unknown)	1
20	Phase II study of docetaxel, cisplatin and 5-FU induction chemotherapy followed by concurrent chemoradiotherapy for advanced nasopharyngeal cancer 2008 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Wei‐Pang Chung, Il Yong Chung	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact